Abstract
Porphyria cutanea tarda (PCT) is the most common form of human porphyria, due to reduced activity of uroporphyrinogen decarboxylase (UROD). There are many factors which can trigger PCT such as viral infections, excessive alcohol intake, iron overload, hepatotoxic drugs and hepatic tumours. Drug induced PCT is well documented but PCT induced by interferon α has rarely been described and only in cases of Hepatitis C Virus (HCV) infection or haematological malignancies.
Here, we report the first case of de novo PCT induced by adjuvant interferon α (IFNα) therapy in a patient with stage II melanoma.Graphical Abstract
Current Drug Safety
Title:Sporadic Porphyria in a Patient with Stage II Melanoma Treated with Interferon α
Volume: 12 Issue: 2
Author(s): V. Reymann*, C. Girard, O. Dereure, B. Guillot and A. Du Thanh
Affiliation:
- Dermatology Department,CHU St Eloi, Montpellier,France
Keywords: Interferon, porphyria, melanoma, PCT, UROD, HCV.
Abstract: Porphyria cutanea tarda (PCT) is the most common form of human porphyria, due to reduced activity of uroporphyrinogen decarboxylase (UROD). There are many factors which can trigger PCT such as viral infections, excessive alcohol intake, iron overload, hepatotoxic drugs and hepatic tumours. Drug induced PCT is well documented but PCT induced by interferon α has rarely been described and only in cases of Hepatitis C Virus (HCV) infection or haematological malignancies.
Here, we report the first case of de novo PCT induced by adjuvant interferon α (IFNα) therapy in a patient with stage II melanoma.Export Options
About this article
Cite this article as:
Reymann V.*, Girard C., Dereure O., Guillot B. and Du Thanh A., Sporadic Porphyria in a Patient with Stage II Melanoma Treated with Interferon α, Current Drug Safety 2017; 12 (2) . https://dx.doi.org/10.2174/1574886312666170502163628
DOI https://dx.doi.org/10.2174/1574886312666170502163628 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Down Regulated Expression of Claudin-1 and Claudin-5 and Up Regulation of β-Catenin: Association with Human Glioma Progression
CNS & Neurological Disorders - Drug Targets Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Cytotoxicity and Anti-inflammatory Activity of Flavonoid Derivatives Targeting NF-kappaB
Recent Patents on Inflammation & Allergy Drug Discovery Virotherapy as An Approach Against Cancer Stem Cells
Current Gene Therapy Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer
Current Topics in Medicinal Chemistry Inhibitors of Cysteine Proteases
Current Topics in Medicinal Chemistry Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology The Transcriptome in Blood: Challenges and Solutions for Robust Expression Profiling
Current Molecular Medicine Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design KSP Inhibitors as Antimitotic Agents
Current Topics in Medicinal Chemistry Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Amphiphilic Oligomers: A New Kind of Macromolecular Carrier of Antimitotic Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Agonists and Antagonists of Protease Activated Receptors (PARs)
Current Medicinal Chemistry Oncogene Suppression by Small Interfering RNAs
Current Pharmaceutical Biotechnology Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry